SCHEMBL20148014

SCHEMBL20148014

CCC1(C(=O)NCC(C)C)CCN(C(C)C)CC1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RET P07949 3/20 0.37
CYP2C19 P33261 2/20 0.36
CYP2D6 P10635 1/20 0.36
KDM4E B2RXH2 2/20 0.35
MMP1 P03956 2/20 0.33
MMP9 P14780 1/20 0.33
MMP13 P45452 1/20 0.33
MMP8 P22894 1/20 0.33
HCN4 Q9Y3Q4 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
RECQL P46063 1/20 0.32
POLB P06746 1/20 0.32
EPHX1 P07099 2/20 0.32
FPR3 P25089 1/20 0.32
FPR2 P25090 1/20 0.32
HRH3 Q9Y5N1 2/20 0.32
CETP P11597 1/20 0.31
HPGD P15428 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20070272 0.88 RET (0.36) RETCYP2C19CYP2D6KDM4EMMP1
SCHEMBL20069765 0.86 CYP2C19 (0.44) RETCYP2C19CYP2D6KDM4EMMP1
SCHEMBL20206001 0.84 RET (0.39) RETCYP2C19CYP2D6KDM4EMMP1
SCHEMBL20206000 0.83 KDM4E (0.45) RETCYP2C19CYP2D6KDM4E
SCHEMBL20158492 0.82 RET (0.40) RETCYP2C19CYP2D6KDM4ERECQL
SCHEMBL20205986 0.82 RET (0.40) RETCYP2C19CYP2D6KDM4ERECQL
SCHEMBL21652001 0.82 RET (0.42) RETSMN1; SMN2HRH3
SCHEMBL18713110 0.81 MME (0.37) RETCYP2D6MMP1MMP9MMP13
SCHEMBL25504417 0.81 CYP2C19 (0.38) RETCYP2C19CYP2D6KDM4EMMP1
SCHEMBL20349551 0.81 RET (0.36) RETCYP2D6MMP1MMP9MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 US disclosed
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2021-01-05 US disclosed
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-10-15 US disclosed
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-08 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 RET 1/4885CYP2C19 4137/4885CYP2D6 3759/4885
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 RET 1/4885CYP2C19 4137/4885CYP2D6 3759/4885
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 RET 1/4885CYP2C19 4137/4885CYP2D6 3759/4885
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 RET 1/4885CYP2C19 4137/4885CYP2D6 3759/4885
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 RET 1/4885CYP2C19 4137/4885CYP2D6 3759/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 RET 1/4885CYP2C19 4137/4885CYP2D6 3759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.